Sermorelin vs GHRH (1–44)
Both Sermorelin and GHRH (1–44) are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
Sermorelin
Evidence B+Sermorelin Acetate (GHRH 1-29)
The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.
View full Sermorelin profile →GHRH (1–44)
Evidence AGrowth Hormone Releasing Hormone, full sequence
The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.
View full GHRH (1–44) profile →Side-by-Side
| Attribute | Sermorelin | GHRH (1–44) |
|---|---|---|
| Evidence Grade | B+ | A |
| FDA Status | FDA-approved (1990) for pediatric growth hormone deficiency; off-label adult use via compounding pharmacies | FDA-approved (Geref) historically as diagnostic GH stimulant; current US availability limited |
| Typical Dose | 200–500 mcg before bed (subcutaneous) | 1 mcg/kg IV (diagnostic test) |
| Clinics Indexed | 220 | 22 |
| Categories | growth-hormone, anti-aging | growth-hormone |
Key reported benefits — Sermorelin
- ✓Natural GH release
- ✓Improved sleep
- ✓Lean body mass
- ✓Recovery
Key reported benefits — GHRH (1–44)
- ✓Endogenous GH stimulation
- ✓Diagnostic GH testing
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.